冠心病治疗单位的药物相互作用:逆境还是治疗成功?
J T S B Gomes1, M C C P Castro2, L L Pereira3
1Hospital de Clínicas, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
Enfermeria intensiva
|November 16, 2024
概括
在冠状动脉护理单位发现潜在药物相互作用 (pDDI) 的高患病率. 心肌梗塞病史,多药和血液作用药物增加了pDDI的风险,影响了患者的健康.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 心脏病学 心脏病学
背景情况:
- 潜在的临床显著药物相互作用 (pDDI) 是冠状动脉护理单位 (CCU) 的一个问题.
- 了解pDDI的患病率和促成因素对于患者安全和有效治疗至关重要.
研究的目的:
- 为了确定CCU患者中pDDI的患病率和相关因素.
- 描述缓解pDDI的临床管理策略.
主要方法:
- 一项涉及120名CCU患者使用两种或两种以上药物的横截面研究.
- 从医疗记录中收集的数据 (2018年5月至2019年4月) 并使用Micromedex工具进行分析.
- 普罗森分布的通用线性模型用于识别与pDDI相关的因素.
主要成果:
- 81.6%的患者经历了严重的PDDI.
- 增加出血风险 (73.8%) 与抗血小板和抗凝固药物组合有关.
- 心肌梗塞,多药和使用血液作用药物是PDDI的重要危险因素.
结论:
- 在CCU患者中存在重度PDDI的高患病率.
- 心肌梗塞,多药和特定药物类增加了pDDI的可能性.
- 协同作用的药物效应可以改善心血管结果,强调需要谨慎的治疗管理.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
456
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
456
Heart Failure Drugs: Inotropic Agents
523
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
523
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K


